Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.

Lavinia DavidescuGrigoriy UrsolOleksii KorzhVikranth DeshmukhLesia KurykMonja-Marie NortjeOlga GodlevskaGilles DevouassouxEduard KhodoshElliot IsraelAlain MoussyColin D MansfieldOlivier HerminePascal Chanez

Published in: Journal of asthma and allergy (2022)

Orally administered masitinib reduces the risk of asthma exacerbations in severe asthma patients, with an acceptable safety profile. Masitinib may potentially provide a new treatment option for oral corticosteroid-dependent severe asthma.

Keyphrases

chronic obstructive pulmonary disease
cystic fibrosis
lung function
double blind
clinical trial
randomized controlled trial
smoking cessation